HROW News and Press, Harrow Health Inc.

A look at the top 10 most actives in the United States Mobix Labs Inc. (MOBX) rose 532.8% to $1.12 on volume of 1,386,331,312 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 15.1% to $2.06 on volume of 1,262,822,550 shares Trio Petroleum Corp. (TPET) rose 74.1% to $1.95 on vo...

NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:4...

2026-03-04 06:46:19 ET Overview My last look at Harrow ( HROW ) was in August 2025. I have been one of the few analysts on the platform who’s expressed caution. But Harrow’s growth is undeniable. Its YoY revenue growth in the past several quarters has been cons...

2026-03-03 17:02:52 ET More on Harrow Health Harrow, Inc. (HROW) Q4 2025 Earnings Call Transcript Harrow Shares Collapse, Another Opportunity? Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update Harrow Health GAAP EPS of $0.17 misses by $0.20, rev...

2026-03-03 17:02:13 ET Harrow, Inc. (HROW) Q4 2025 Earnings Call March 3, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the Board & Founder Andrew Boll - President, C...

2026-03-03 14:24:23 ET Harrow, Inc. ( HROW ) is a name we have previously identified for now 3 speculative trades, which can be read, here , here and here. We do like it for the long-term investor, but folks this has been a great trading stock, and one that members of BA...

2026-03-03 11:01:51 ET Image source: The Motley Fool. Tuesday, March 3, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to support a plann...

2026-03-02 16:26:04 ET More on Harrow Health Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update Harrow: Flirting With Missing 2025 Revised Guidance Seeking Alpha’s Quant Rating on Harrow Health Historical earnings data for Harrow Health ...

Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024 GAAP net income of $6.6 milli...